APA

Largeaud L., Bérard E., Bertoli S., Dufrechou S., Prade N., Gadaud N., Tavitian S., Bories P., Luquet I., Sarry A., De Mas V., Huguet F., Delabesse E. & Récher C. (20200521). Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. : Leukemia research.

Chicago

Largeaud Laetitia, Bérard Emilie, Bertoli Sarah, Dufrechou Stéphanie, Prade Naïs, Gadaud Noémie, Tavitian Suzanne, Bories Pierre, Luquet Isabelle, Sarry Audrey, De Mas Véronique, Huguet Françoise, Delabesse Eric and Récher Christian. 20200521. Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. : Leukemia research.

Harvard

Largeaud L., Bérard E., Bertoli S., Dufrechou S., Prade N., Gadaud N., Tavitian S., Bories P., Luquet I., Sarry A., De Mas V., Huguet F., Delabesse E. and Récher C. (20200521). Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. : Leukemia research.

MLA

Largeaud Laetitia, Bérard Emilie, Bertoli Sarah, Dufrechou Stéphanie, Prade Naïs, Gadaud Noémie, Tavitian Suzanne, Bories Pierre, Luquet Isabelle, Sarry Audrey, De Mas Véronique, Huguet Françoise, Delabesse Eric and Récher Christian. Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. : Leukemia research. 20200521.